% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Forster:276333,
      author       = {T. Forster and C. Köhler and M. Dorn and M. F. Häfner and
                      N. Arians and L. König and S. B. Harrabi and I. Schlampp
                      and F. Weykamp and E. Meixner and K. Lang and V. Heinrich
                      and N. Weidner and J. Hüsing and M. Wallwiener and M.
                      Golatta and A. Hennigs and J. Heil and H. Hof and D. Krug
                      and J. Debus$^*$ and J. Hörner-Rieber$^*$},
      title        = {{N}on-inferiority of local control and comparable toxicity
                      of intensity-modulated radiotherapy with simultaneous
                      integrated boost in breast cancer: 5-year results of the
                      {IMRT}-{MC}2 phase {III} trial: {IMRT}-{SIB} is non-inferior
                      to 3-{D}-{CRT}-seq{B} in {RT} for {BC} patients.},
      journal      = {International journal of radiation oncology, biology,
                      physics},
      volume       = {117},
      number       = {4},
      issn         = {0360-3016},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DKFZ-2023-01063},
      pages        = {857-868},
      year         = {2023},
      note         = {2023 Nov 15;117(4):857-868 / #LA:E050#},
      abstract     = {The IMRT-MC2 trial was conducted to demonstrate
                      non-inferiority of conventionally fractionated
                      intensity-modulated radiotherapy with simultaneous
                      integrated boost (IMRT-SIB) to 3-D-conformal radiotherapy
                      with sequential boost (3-D-CRT-seqB) for adjuvant breast
                      radiotherapy.A total of 502 patients were randomized between
                      2011 and 2015 for the prospective, multicenter,
                      phase-III-trial (NCT01322854). 5-year results of late
                      toxicity (LENT-SOMA), overall survival, disease-free
                      survival, distant disease-free survival, cosmesis (Harvard
                      scale) and local control (non-inferiority margin at hazard
                      ratio of 3.5) were analyzed after a median follow-up of 62
                      months.The 5-year LC rate for the IMRT-SIB arm was
                      non-inferior to the control arm $(98.7\%$ vs. $98.3\%,$
                      respectively; HR 0.582, $95\%-CI:$ [0.119-2.375], p=0.4595).
                      Furthermore, there was no significant difference in overall
                      survival $(97.1\%$ versus $98.3\%,$ respectively; HR 1.235,
                      $95\%-CI:$ [0.472-3.413], p=0.6697), disease-free survival
                      $(95.8\%$ versus $96.1\%,$ respectively; HR 1.130,
                      $95\%-CI:$ [0.487-2.679], p=0.7758) and distant disease-free
                      survival $(97.0\%$ versus $97.8\%,$ respectively; HR 1.667,
                      $95\%-CI:$ [0.575-5.434], p=0.3601). After 5 years, late
                      toxicity evaluation and cosmetic assessment further showed
                      no significant differences between treatment arms.The 5-year
                      results of the IMRT-MC2 trial provide strong evidence, that
                      the application of conventionally fractionated simultaneous
                      integrated boost irradiation for breast cancer patients is
                      both safe and effective with non-inferior local control
                      compared to 3-D-conformal radiotherapy with sequential
                      boost.},
      keywords     = {3-D-conformal radiotherapy (Other) / 5-year follow-up
                      (Other) / Breast cancer (Other) / intensity-modulated
                      radiotherapy (IMRT) (Other) / local control (Other) /
                      overall survival (Other) / sequential boost irradiation
                      (Other) / simultaneously integrated boost (SIB) (Other)},
      cin          = {E050 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)E050-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {315 - Bildgebung und Radioonkologie (POF4-315)},
      pid          = {G:(DE-HGF)POF4-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37244626},
      doi          = {10.1016/j.ijrobp.2023.05.035},
      url          = {https://inrepo02.dkfz.de/record/276333},
}